硼中子捕获疗法（BNCT）是一种再次出现的二进制细胞水平癌症干预方法，通过肿瘤特异性的10硼（10B）药物与中子的相互作用来实现。我们创造了一种新的10B药物，3硼代L-酪氨酸（BTS），它在主要历史性BNCT药物4硼代L-苯丙氨酸（BPA）的特性上有所提高。BTS在体外的摄取量可以比BPA高4倍，并且具有更高的细胞保留率。与BPA一样，BTS的摄取是通过L型氨基酸转运体-1（LAT1）介导的，但对天然氨基酸的竞争更不敏感。BTS可以制成注射液，并且剂量可以比BPA高得多，导致体内的硼传递量增加2-3倍。快速血液清除和更高的肿瘤硼传递量导致更高的肿瘤-血液比例。BTS的硼传递量似乎与LAT1的表达相关。BTS是一种有潜力改善现代BNCT干预的有前景的硼传递药物。

Boron neutron capture therapy (BNCT) is a re-emerging binary cellular level cancer intervention that occurs through the interaction of a cancer-specific 10boron (10B) drug and neutrons. We created a new 10B drug, 3-borono-l-tyrosine (BTS), that improves on the characteristics of the main historical BNCT drug 4-borono-l-phenylalanine (BPA). BTS has up to 4 times greater uptake in vitro than BPA and increased cellular retention. Like BPA, BTS uptake is mediated by the l-type amino acid transporter-1 (LAT1) but is less sensitive to natural amino acid competition. BTS can be formulated and bolus dosed at much higher levels than BPA, resulting in 2-3 times greater boron delivery in vivo. Fast blood clearance and greater tumor boron delivery result in superior tumor-to-blood ratios. BTS boron delivery appears to correlate with LAT1 expression. BTS is a promising boron delivery drug that has the potential to improve modern BNCT interventions.